GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE332nnn/GSE332566/primaryOK200Methylation profilingHomo sapiensMethylation profiling by genome tiling arrayhttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE332566GEOGSEfalseStudy of the predictive value of genomic, transcriptomic and epigenetic biomarkers in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with PD-1/PD-L1 inhibitorsImmune checkpoint inhibitors have improved survival in several solid tumors, including head and neck squamous cell carcinoma (HNSCC). However, current use of PD-1/PD-L1 inhibitors relies on PD-L1 expression, which does not reliably predict patient response. Therefore, better predictive biomarkers are needed to identify which patients benefit from immunotherapy. Previous studies suggest that genomic and transcriptomic features may help predict treatment response.2026/05/25GSE332566GSM9750846GSM9750847GSM9750848GSM9750849GSM9750850GSM9750851GSM9750852GSM9750853GSM9750854GSM9750855GSM9750834GSM9750856GSM9750857GSM9750835GSM9750858GSM9750836GSM9750837GSM9750859GSM9750838GSM9750839GSM9750840GSM9750841GSM9750842GSM9750843GSM9750844GSM975084534510332566Homo sapiens